$4.4 M

IMUN Mkt cap, 08-Oct-2018

$65 K

Immune Therapeutics Revenue Q2, 2018
Immune Therapeutics Gross profit (Q2, 2018)31.8 K
Immune Therapeutics Gross profit margin (Q2, 2018), %49%
Immune Therapeutics Net income (Q2, 2018)-5.1 M
Immune Therapeutics EBIT (Q2, 2018)-2.6 M

Immune Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

16.2k3.5k

Revenue growth, %

(79%)

R&D expense

22.0m977.2k444.2k399.4k

General and administrative expense

71.1m4.1m2.7m3.9m2.8m

Operating expense total

96.0m4.1m15.8m14.3m5.9m

EBIT

(96.0m)(45.3m)(15.8m)(14.3m)(5.9m)

EBIT margin, %

(97567%)(412125%)

Interest expense

1.4m388.2k271.0k3.4m1.2m

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)(7.9m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.1k5.6k5.0k3.5k65.0k65.0k

Cost of goods sold

33.2k33.2k

Gross profit

31.8k31.8k

Gross profit Margin, %

49%49%

R&D expense

6.4m4.2m401.4k414.5k111.4k67.3k247.0k118.7k129.2k185.7k

General and administrative expense

12.6m12.6m3.7m901.7k402.0k443.6k865.3k939.3k893.9k1.0m666.1k620.9k638.2k1.8m

Operating expense total

19.7m17.5m3.7m7.1m402.0k2.5m2.6m939.3k2.6m2.7m1.5m1.4m1.0m2.6m

Depreciation and amortization

557.0

EBIT

(19.7m)(17.5m)(6.5m)(7.1m)(2.9m)(2.5m)(2.6m)(5.0m)(2.6m)(2.7m)(1.5m)(1.4m)(988.3k)(2.6m)

EBIT margin, %

(139486%)(43405%)(51460%)(143795%)(1520%)(3948%)

Interest expense

205.4k161.1k121.0k94.1k18.0k50.7k79.9k301.4k1.1m978.3k575.8k118.9k220.5k462.0k

Net Income

(19.9m)(17.7m)(11.2m)(2.9m)(2.6m)(4.0m)(6.6m)(4.0m)(3.9m)(2.7m)(1.6m)(731.9k)(5.1m)

Immune Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

406.6k192.0k23.1k74.4k14.7k

Accounts Receivable

16.2k

Inventories

178.1k

Current Assets

622.5k222.0k39.3k74.4k192.8k

Total Assets

19.2m6.1m41.2k76.4k195.5k

Accounts Payable

839.9k2.1m1.9m1.8m2.3m

Short-term debt

817.2k

Current Liabilities

2.4m3.4m6.0m9.2m11.3m

Long-term debt

817.2k

Non-Current Liabilities

121.1k327.5k

Total Debt

1.6m

Total Liabilities

2.6m3.7m6.0m9.2m11.3m

Additional Paid-in Capital

308.1m338.0m343.4m360.4m366.6m

Retained Earnings

(283.0m)(333.5m)(349.9m)(365.7m)(373.0m)

Total Equity

16.6m2.4m(9.1m)(11.1m)

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.2 x2.6 x0 x0 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

207.7k233.7k58.7k58.6k30.9k22.4k153.9k132.8k64.3k22.2k98.1k45.0k22.6k30.4k

Accounts Receivable

2.1k7.7k12.7k19.7k2.7k

Inventories

214.3k158.6k158.6k

Current Assets

252.7k276.2k93.7k108.3k62.9k60.1k211.9k153.4k78.2k22.2k98.1k45.0k236.9k189.0k158.6k

Total Assets

19.5m18.1m17.3m16.6m5.7m5.6m5.6m154.8k79.1k22.8k100.0k48.3k239.9k193.3k163.7k

Accounts Payable

629.8k1.0m1.6m1.8m1.9m1.9m1.9m1.9m1.5m1.5m1.7m1.8m2.2m2.4m1.7m

Short-term debt

857.2k1.4m

Current Liabilities

2.4m3.2m4.0m2.7m3.7m3.9m4.6m6.3m7.0m7.5m10.4m7.9m8.6m11.4m9.8m

Long-term debt

857.2k1.4m

Non-Current Liabilities

121.1k101.1k71.1k354.4k429.0k109.3k

Total Debt

1.7m2.8m

Total Liabilities

2.5m3.3m2.7m4.4m4.7m7.0m7.5m10.4m7.9m8.6m11.4m9.8m

Additional Paid-in Capital

272.7m322.6m324.4m338.4m339.8m340.2m343.9m351.3m354.3m357.4m361.5m364.8m365.3m367.2m367.8m

Retained Earnings

(236.3m)(300.7m)(307.3m)(318.5m)(336.6m)(338.8m)(342.6m)(354.4m)(358.3m)(362.3m)(368.3m)(368.0m)(369.4m)(373.6m)(377.7m)

Total Equity

17.0m14.8m13.3m13.9m1.7m1.2m935.3k(6.9m)(7.5m)(10.3m)(7.9m)(8.4m)(11.2m)(9.6m)

Financial Leverage

1.1 x1.2 x1.3 x1.2 x3.4 x4.6 x6 x0 x0 x0 x0 x0 x0 x0 x

Immune Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(106.1m)(49.9m)(16.9m)(19.8m)

Depreciation and Amortization

2.9m2.5k594.8k1.6k826.0

Accounts Receivable

(16.2k)13.5k

Inventories

246.3k40.0k(178.1k)

Accounts Payable

553.2k1.8m900.5k541.0k919.1k

Cash From Operating Activities

(3.8m)(2.8m)(2.8m)(2.1m)

Cash From Investing Activities

(58.5k)(1.5k)

Long-term Borrowings

(100.0k)(75.9k)(319.9k)

Cash From Financing Activities

3.7m2.7m2.9m2.0m

Interest Paid

4.5k20.5k29.6k43.0k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Net Income

(59.3m)(17.7m)(35.5m)(2.9m)(5.5m)(9.5m)(6.6m)(10.7m)(14.6m)(2.7m)(2.6m)(731.9k)(5.1m)

Depreciation and Amortization

2.1m719.3k2.2m297.5k446.1k981.01.3k144.0288.0434.0867.0

Accounts Receivable

2.1k(7.7k)(12.7k)19.7k13.5k13.5k

Inventories

19.5k19.5k

Accounts Payable

343.1k175.4k1.6m1.1m1.9m(158.9k)605.6k1.9m104.1k103.2k138.8k239.8k78.2k521.8k

Cash From Operating Activities

(1.3m)(1.9m)(1.4m)(2.3m)(529.4k)(1.2m)(455.8k)(870.1k)

Cash From Investing Activities

(1.5k)(2.0k)(13.6k)

Cash From Financing Activities

1.1m1.9m1.4m2.3m553.2k1.2m473.5k869.0k

Interest Paid

12.0k10.3k18.7k13.0k9.0k15.2k34.7k
Report incorrect company information